July 23, 2007

/Everett White/

PTO/SB/08A (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	Under the Paperwork Reduction Act of 1995, no persons are required to r	espond to a collection of informat	tion unless it contains a valid QMB control number.		
	Substitute for form 1449/PTO	Complete if Known			
		Application Number	10/580,512		
	INFORMATION DISCLOSURE	Filing Date	May 23, 2006		
		First Named Inventor	Ichikawa, Yoshitaka		
	STATEMENT BY APPLICANT	Art Unit	1614		
	(Use as many sheets as necessary)	Examiner Name	TBA		
_	Sheet 1 of 4	Attorney Docket Number	8031-013-US		

			U. S. PATENT D		
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
		Number-Kind Code ^{2 (# 2109m)}			Figures Appear
/EW/		^{US-} 3,683,076	08-08-1972		
/EW/		^{US-} 4,870,061	09-26-1989		
/EW/		US 5,840,715	11-24-1998		
/EW/		^{US-} 6,136,795	10-24-2000		
		US-			
		US-			
		US-			
		US-	-		
		US-			
		US-			
	-	US-			
		US-			
		US-	1		
	_	US-			
		US-	,		
		U\$-			
		US-		*	
		US-	+		-
_		US-	+		_

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	П
		Country Code ⁵ "Number ⁴ " Kind Code ⁵ (if known)	MM-DD-YYYY	•	Or Relevant Figures Appear	T ⁶
/EW/		PCT/US02/09859	10-10-2002			
						L
	_		-			-
						<u> </u>

EXAMPLES install if reterrors considered, whether or not clasted is in conformance with MPEP 600 Date line through clastics of their in conformance area and considered, include copy of this stem with next communication to applicate. Application straight clasted independent on unable (optionals or 0 USPTO Pattert Documents at west standards or MPEP 001.04. "Entire Otition that issued the document by the how-better code (WPO) Standard ST3.5." For Japanese pattern documents, the indication of the year of the region of the Tripperor most procedule he seed in standard of the pattert documents of the conformation of the year of the region of the Tripperor most procedule he seed in standard of the pattert document with the appropriate symbols as indicated on the document under WIPO Standard ST3.16 if possible. "Applicant is to place a check mark here if English language Translation is standarded.

Date

Considered

08/12/2009

Immateria is statistical.

This collection of This collection of Immateria by 37 CFR 197 and 1.98. This information is required to obtain or return a bonefit by the public which is to fix (and by the This collection of Immaterial Confidentiality) agreemed by 35 U.S.C. 122 and 37 CFR 114. This collection is extended to the Confidentiality agreemed by 35 U.S.C. 122 and 37 CFR 114. This collection is extended to Durants o complete, recision gathering, inequality, and submitting the completed application form to the USPTO. There will vary depending upon the information cannot be completed to the complete this form and/or suppressions for reducing this burst, shocked be sent to the Chief Information of the Complete this form and/or suppressions for reducing this burst, shocked be sent to the Chief Information and Trademark Office, P.O. Box 1450, Alexandria, V.A. 22313-1450, DO NOT STND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Data 1450, Alexandria, V.A. 22313-1450, DO NOT STND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Data 1450, Alexandria, V.A. 22313-1450, DO NOT STND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Data 1450, Alexandria, V.A. 22313-1450, DO NOT STND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 22313-1450, DO NOT STND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 22313-1450, DO NOT STND FEES OR COMPLETED FORMS TO THIS ADDRESS.

PTO/SB/08B (04-07)

Approved for use through 09/30/2007, OMB 0851-0031 U.S. Patent and Trademerk Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons an Substitute for form 1449/PTO	re required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
Substitute for Still 1-4-air 1-5	Application Number	10/580,512	
INFORMATION DISCLOSURE	Filing Date	May 23, 2006	
STATEMENT BY APPLICANT	First Named Inventor	Ichikawa, Yoshitaka	
(Use as many sheets as necessary)	Art Unit	1614	
(050 as many sincers as necessary)	Examiner Name	TBA	
Sheet 2 of 4	Attorney Docket Number	8031-013-US	

		NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²				
/EW/		ALTMAN, R. D., et al., "Practice Guidelines in the Management of Osteoarthritis," Osteoarthritis and Cartilage, (1998), 6(Supp.A):22-24.					
		BOHNE, W., "Glukosamine In Der Konsenvativen Arthrosebehandlung," Med. Welt. Nr., (1969), 30:1668-1671.					
/EW/		CHU, S. C., et al., "Analysis of the Cytokin-Stimulated Human Inducible Nitric Oxide Synthase (iNOS) Gene," Biochem. Biophys. Res. Commun., (1998), 248:871-878.					
/EW/		CHOU, T., et al., "Glycosylation of the c-Myc transactivation domain," Proc. Natl. Acad. Sci. USA, (1995), 92:4417-4421.					
/EW/		DE VRIES, B. J., et al., "Quantitation of glycosaminoglycan metabolism in anatomically intact articular cartilage of the mouse", Rheumatol. Int. (1986) 6,6:273-281.					
		DIEPPE, P., "Melecular Markers for Joint and Skoletal Diseases: Notes from the General Discussion," Acta. Orthop. Scand., (1995), 66(Supp.266):211-212.					
		FINGL, E. et al., "The Pharmacological Basis of Therapeutics," (1975), Chapter 1:1-46.					
/EW/		GABRIEL, S. E., et al, "Direct Medical Costs Unique to People with Arthritis," J. Rheumatol., (1997), 24:719-725.					
/EW/		GENG, Y., et al., "Tyrosine Kinases Are Involved With the Expression of Inducible Nitric Oxide Synthase in Human Articular," J. Cell. Physiol., (1995), 163:545-554.					
/EW/		HALTIWANGER, R. S., et al., "O-Glycosylation of Nuclear and Cytoplasmic Proteins: Regulation Analogous," Biochem. Biophys. Res. Commun., (1997), 231:237-242.					

Signature	/Everett White/		Considered	08/10/2009	
*EXAMINER: I	nitial if reference considered, whether or not citation is in conformance with M	PEP 609	Draw line through c	itation if not in conformance and not	

Date

Examiner

considered. Include copy of this form with next communication to applicant.

considers. Indused copy or ins from with next communitation to appose and.

A popilicants unique cotation designation number (optional). A popilicant is not put on the first plant language. Transition is not stacked.

A popilicant is unique cotation designation number (optional). A popilicant is not put of the communitation is not stacked.

A popilicant is unique considerable to the communitation of the communitation is not stacked.

This collection is estimated to take 2 monitor of the communitation of the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTC/SB/08B (04-07)

Approved for use through 09/30/2007, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons as	U.S. Patient and Fracelank Officer (U.S. DePARK Meth OF Commerce required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
Substitute for four First FO	Application Number	10/580,512	
INFORMATION DISCLOSURE	Filing Date	May 23, 2006	
STATEMENT BY APPLICANT	First Named Inventor	Ichikawa, Yoshitaka	
(Use as many sheets as necessary)	Art Unit	1614	
(Use as many shows as necessary)	Examiner Name	ТВА	
Sheet 3 of 4	Attorney Docket Number	8031-013-US	

NON PATENT LITERATURE DOCUMENTS					
Examinater Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²			
/EW/ HEVEL, J. M., et al., "Nitric-Oxide Synthase Assays," Methods Enzymol., (1994), 233:250-258.					
/EW/ HOCHBERG, M. C., et al., "Guidelines for the Medical Management of Osteoarthritis," Arthritis & Rheumatism, (1995), 38(11):1535-1546.					
/EW/		INEROT, S., et al., "Articular-Cartilage Proteoglycans in Aging and Osteoarthritis," Biochem. J., (1978), 169:143-156.			
/EW/ KORNFELD, S., et al., "The Feedback Control of Sugar Nucleotide Biosynthesis in Liver, " Proc. Natl. Acad. Sci. USA, (1964), 52:371-379.					
/EW/ KOLM-LITTY, J., et al., "High Glucose-Induced Transforming Growth FactorB1 Production is Mediated by the Hexosamine Pathway," J. Clin. Invest., (1998), 101(1):180-169.					
/EW/		KARIN, M., "The Beginning of the End: IkB Kinase (IKK) and NF-kB Activation," J. Biol. Chem., (1999), 274(39):27339-27342.			
/EW/		LAWRENCE, R. C., et al., "Estimates of the Prevalence of Arthritis and Selected Musculoskeletal Disorders," Arthritis & Rheumatism, (1998), 41(5):778-799.			
/EW/ LOZADA, C. J., et al., "Chondroprotection in Osteoarthritis," Bull. Rheum. Dis., (1997), 46(7):5-7. /EW/ MEVORACH, D., et al., "Osteoarthritis and Chondroprotection," Isr. J. Med. Sci., (1994), 30:928-931.					
/EW/		MARCH, L. M., et al., "Economics of Osteoarthritis: A Global Perspective," Balliere's Clinical Rheumatology, (1997), 11(4):817-834.			

Signature /Everett White	/	Considered	08/10/2009
*EXAMINER: Initial if reference considered w	whether or not citation is in conformance with MPEP 605	Draw line through o	itation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

I Agrilland's unique citation designation number (optional). 2-Agrilland to be place a check mark here it English Inapuage Transition is attached.

This collection of information is required by 37 CH+10.8. The information is required to obtain or retain a bornetit by the public which is to the (and by the USP) To to process) an application. Confidentiality is governed by 36 U.S.C. 122 and 37 CHF+1.4. This collection is destinated to take 2 hours to complete, including interpretations, and submitting the completed application forms to the USP.TO. This will vary depending upon the individual case. Any comments on the option of the process of the complete application forms to the USP.TO. The will vary depending upon the individual case. Any comments on the Trademark Orber, P.C. Box 1460, Alexandria, VA 22313-1460. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patternis, P.O. Box 1450, Alexandria, VA 22313-1460.

PTC/SB/08B (04-07) Approved for use through 09/30/2007. OM8 0651-0031

Approved for use through 0930/2007. OM8 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
or the Pagesyork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO	required to respond to a collection of information unless it contains a valid OMB control number Complete if Known		
Substitute for form 1445/110	Application Number	10/580,512	
INFORMATION DISCLOSURE	Filing Date	May 23, 2006	
STATEMENT BY APPLICANT	First Named Inventor	Ichikawa, Yoshitaka	
(Use as many sheets as necessary)	Art Unit	1614	
tose as many sireets as necessary)	Examiner Name	ТВА	
Sheet 4 of 4	Attorney Docket Number	8031-013-US	

		NON PATENT LITERATURE DOCUMENTS				
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of Initials* No. the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²				
/EW/		NEWTON, R., et al., "Superinduction of COX-2 mRNA By Cycloheximide and Interleukin-1B Involves Increased Transcription and Correlates," FEBS Letters, (1997), 418:135:138.				
/EW/		PARIKH, A. A., et al., "IL-6 Production in Human Intrestinal Epithelial Cells Following Stimulation with IL-1 B Is Associated," J. Clin. Research, (1997), 69:139-144.				
/EW/		SANDY, J. D., et al., "Chondrocyte-Mediated Catabolism of Aggrecan: Aggrecanase- Dependent Cleavage Induced by Interleukin-1," Biochem. J. (1998), 335:59-66.				
		NDY, J. D., et al., "Chondrocyte-Mediated Catabolism of Aggrecan: Evidence for a cosylphosphatidylinositol-Linked," Arch. Biochem. Biophys. (1999), 367(2):258-264.				
		SETNIKAR L et al. "Antireactive properties of Glucosamine Sulfate."				
		Arzneim-Forsch./Drug Res, (1991), 41(1):157-161.				
/EW/		SCHARSTUHL, A., et al., "Loss of Transforming Growth Factor Counteraction on Interleukin 1 Mediated Effects in Cartilage of Old Mice," Ann. Rheum. Dis., (2002), 61:1095-1098.				

Signature	/Everett White/	Considered	08/10/2009
LXamille	/F M. Nation /	Date	08/10/2009

^{*}EXAMINER: Initial if reference considered, whether or not clinifion is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is a fife (and by the USFO) to proceed an application. Confidentiality is geometed by \$3 U.S. 0.12 and \$3.75 FR! 1.4. This collection is estimated to bits 2 hours to complete cubiding galbating, propaging, and submitting the completed application form to the USFIO. Time will vary depending upon the individual case. Any comments on the manuant of line you require to complete this form anders suggestions for recluding this burden, should be sent to the Clinic Information Office, U.S. Patent and Trademark Office, P.O. Bos. 1450, Alexandris, VA.22313-1450. DO NOT SEND FIES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Bos. 1450, Alexandris, VA.22313-1450.